MetaVia Inc.(MTVA)Earnings, Financials & Key Ratios

MTVA•NASDAQ

$1.58

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryMetabolic and Obesity Therapies

AboutMetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.Show more

Revenue$0
EBITDA-$14M+52.4%
Net Income-$13M+53.0%
EPS (Diluted)-7.35+81.2%
ROE-195.61%+12.7%

MTVA Price & Volume

MetaVia Inc. (MTVA) stock price & volume — 10-year historical chart

Loading chart...

Persistent Clinical Burn Strains MetaVia Liquidity Position

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Liquidity and clinical execution

Key Thesis Takeaways

MetaVia remains a high-risk, pre-revenue biotechnology entity entirely dependent on external capital to fund its GPR119-targeted cardiometabolic pipeline.
The company's reliance on equity-based financing is evidenced by an accumulated deficit of $152.7 million, which continues to weigh heavily on its equity base.
Investors should monitor the firm's ability to achieve clinical milestones, as the current cash runway of $13.7 million appears insufficient to sustain long-term operations without further dilutive capital raises.

Verdict Logic

the company's persistent cash burn and the lack of commercial revenue, evidenced by a $4.3 million free cash flow deficit in 2026Q1, present substantial risks to shareholder value.

MTVA Growth Metrics

MetaVia Inc. (MTVA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM46.54%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM83.69%

Return on Capital

10 Years-172.66%

5 Years-120.09%

3 Years-117.66%

Last Year-38.36%

Latest MTVA News

Recent stock market news and headlines for MetaVia Inc. (MTVA)

PRNewsWire·Jun 17, 2026

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

CAMBRIDGE, Mass., June 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Wednesday, June 24, 2026 at 10:30 am ET.

Peers Comparison

Key metrics vs top competitors for MetaVia Inc. (MTVA)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
MTVAMetaVia Inc.Current	$1.58	$3.48M	-0.22	—	—	-195.61%	—
MVISMicroVision, Inc.	$0.38	$125.32M	-1.08	-74.28%	-5887.77%	-139.2%	—
VUZIVuzix Corporation	$2.47	$205.4M	-5.88	9.14%	-504.14%	-87.47%	—
KOPNKopin Corporation	$3.79	$692.35M	259.25	-23.58%	4.86%	4.31%	—
IMMRImmersion Corporation	$6.50	$215.15M	-32.50	11.97%	-0.27%	-0.84%	—
METAMeta Platforms, Inc.	$615.58	$1.56T	26.21	22.17%	32.84%	33.22%	—

Compare MTVA vs Peers

MetaVia Inc. (MTVA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs MVIS

Most directly comparable listed peer for MTVA.

Scale Benchmark

vs NVDA

Larger-name benchmark to compare MTVA against a more recognizable public peer.

Peer Set

Compare Top 5

vs MVIS, VUZI, KOPN, IMMR

Get notified when MTVA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

MTVA Frequently Asked Questions

MetaVia Inc. (MTVA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is MTVA profitable?

MetaVia Inc. (MTVA) reported a net loss of $13.1M for fiscal year 2025.

Dividend & Returns

What is MTVA's return on equity?

MetaVia Inc. (MTVA) has a return on equity (ROE) of -195.6%. Negative ROE indicates the company is unprofitable.

What is MetaVia Inc.'s free cash flow?

MetaVia Inc. (MTVA) had negative free cash flow of $15.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in MTVA back in 2014?

Total return calculator · dividends reinvested · 12+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

MTVAMetaVia Inc.Current

$1.58

$3.48M

-0.22

—

-195.61%

—

MVISMicroVision, Inc.

$0.38

$125.32M

-1.08

-74.28%

-5887.77%

-139.2%

—

VUZIVuzix Corporation

$2.47

$205.4M

-5.88

9.14%

-504.14%

-87.47%

—

KOPNKopin Corporation

$3.79

$692.35M

259.25

-23.58%

4.86%

4.31%

—

IMMRImmersion Corporation

$6.50

$215.15M

-32.50

11.97%

-0.27%

-0.84%

—

METAMeta Platforms, Inc.

$615.58

$1.56T

26.21

22.17%

32.84%

33.22%

—